메뉴 건너뛰기




Volumn 46, Issue 2, 2014, Pages 164-169

A simple rule to personalize standard dual therapy across all genotypes in naive chronic hepatitis C patients: The TT4 randomized trial

(23)  Francioso, Simona a   Almerighi, Cristiana a   Forte, Paolo b   Bandiera, Franco c   Nosotti, Lorenzo d   Lionetti, Raffaella e   Taliani, Gloria f   Piras, Maria Rosaria g   Ponti, Maria Laura g   Parruti, Giustino h   Di Candilo, Francesco i   Gentile, Silvia a   Piccolo, Paola a   Salso, Angela a   Riccobelli, Francesca a   Renzi, Sara b   Longo, Maria Antonella e   Montalbano, Marzia e   Zaru, Salvatore c   Biliotti, Elisa f   more..


Author keywords

Dual therapy; HCV treatment; Individualized therapy; Pegylated interferon; Rapid viral response; Response guided therapy; Ribavirin

Indexed keywords

ALANINE AMINOTRANSFERASE; GAMMA GLUTAMYLTRANSFERASE; GLUCOSE; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RECOMBINANT ERYTHROPOIETIN; RIBAVIRIN; VIRUS RNA;

EID: 84893680059     PISSN: 15908658     EISSN: 18783562     Source Type: Journal    
DOI: 10.1016/j.dld.2013.10.002     Document Type: Article
Times cited : (3)

References (34)
  • 1
    • 0030933395 scopus 로고    scopus 로고
    • Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups
    • Poynard T., Bedossa P., Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 1997, 349:825-832.
    • (1997) Lancet , vol.349 , pp. 825-832
    • Poynard, T.1    Bedossa, P.2    Opolon, P.3
  • 3
    • 0033932001 scopus 로고    scopus 로고
    • Recovery, persistence, and sequelae in hepatitis C virus infection: a perspective on long-term outcome
    • Alter H.J., Seeff L.B. Recovery, persistence, and sequelae in hepatitis C virus infection: a perspective on long-term outcome. Seminars in Liver Disease 2000, 20:17-35.
    • (2000) Seminars in Liver Disease , vol.20 , pp. 17-35
    • Alter, H.J.1    Seeff, L.B.2
  • 4
    • 17344370538 scopus 로고    scopus 로고
    • Prognosis of chronic hepatitis C: results of a large prospective cohort study
    • Niederau C., Lange S., Heintges T., et al. Prognosis of chronic hepatitis C: results of a large prospective cohort study. Hepatology 1998, 28:1687-1695.
    • (1998) Hepatology , vol.28 , pp. 1687-1695
    • Niederau, C.1    Lange, S.2    Heintges, T.3
  • 5
    • 15644380122 scopus 로고    scopus 로고
    • Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy
    • Marcellin P., Boyer N., Gervais A., et al. Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy. Annals of Internal Medicine 1997, 127:875-881.
    • (1997) Annals of Internal Medicine , vol.127 , pp. 875-881
    • Marcellin, P.1    Boyer, N.2    Gervais, A.3
  • 6
    • 84870454347 scopus 로고    scopus 로고
    • Treatment indication and response to standard of care with peginterferon and ribavirin in acute and chronic HCV infection
    • Feld J.J. Treatment indication and response to standard of care with peginterferon and ribavirin in acute and chronic HCV infection. Best Practice & Research Clinical Gastroenterology 2012, 26:429-444.
    • (2012) Best Practice & Research Clinical Gastroenterology , vol.26 , pp. 429-444
    • Feld, J.J.1
  • 7
    • 65449152185 scopus 로고    scopus 로고
    • Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection
    • McHutchison J.G., Everson G.T., Gordon S.C., et al. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. New England Journal of Medicine 2009, 360:1827-1838.
    • (2009) New England Journal of Medicine , vol.360 , pp. 1827-1838
    • McHutchison, J.G.1    Everson, G.T.2    Gordon, S.C.3
  • 8
    • 65449171953 scopus 로고    scopus 로고
    • Telaprevir and peginterferon with or without ribavirin for chronic HCV infection
    • Hezode C., Forestier N., Dusheiko G., et al. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. New England Journal of Medicine 2009, 360:1839-1850.
    • (2009) New England Journal of Medicine , vol.360 , pp. 1839-1850
    • Hezode, C.1    Forestier, N.2    Dusheiko, G.3
  • 9
    • 77956268467 scopus 로고    scopus 로고
    • Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial
    • Kwo P.Y., Lawitz E.J., McCone J., et al. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial. Lancet 2010, 376:705-716.
    • (2010) Lancet , vol.376 , pp. 705-716
    • Kwo, P.Y.1    Lawitz, E.J.2    McCone, J.3
  • 10
    • 84865560854 scopus 로고    scopus 로고
    • Cost-effectiveness of boceprevir or telaprevir for untreated patients with genotype 1 chronic hepatitis C
    • Cammà C., Petta S., Enea M., et al. Cost-effectiveness of boceprevir or telaprevir for untreated patients with genotype 1 chronic hepatitis C. Hepatology 2012, 56:850-860.
    • (2012) Hepatology , vol.56 , pp. 850-860
    • Cammà, C.1    Petta, S.2    Enea, M.3
  • 11
    • 84858432382 scopus 로고    scopus 로고
    • A practical guide for the use of boceprevir and telaprevir for the treatment of hepatitis C
    • Jacobson I.M., Pawlotsky J.M., Afdhal N.H., et al. A practical guide for the use of boceprevir and telaprevir for the treatment of hepatitis C. Journal of Viral Hepatitis 2012, 19:1-26.
    • (2012) Journal of Viral Hepatitis , vol.19 , pp. 1-26
    • Jacobson, I.M.1    Pawlotsky, J.M.2    Afdhal, N.H.3
  • 12
    • 84857368831 scopus 로고    scopus 로고
    • UK consensus guidelines for the use of the protease inhibitors boceprevir and telaprevir in genotype 1 chronic hepatitis C infected patients
    • Ramachandran P., Fraser A., Agarwal K., et al. UK consensus guidelines for the use of the protease inhibitors boceprevir and telaprevir in genotype 1 chronic hepatitis C infected patients. Alimentary Pharmacology and Therapeutics 2012, 35:647-662.
    • (2012) Alimentary Pharmacology and Therapeutics , vol.35 , pp. 647-662
    • Ramachandran, P.1    Fraser, A.2    Agarwal, K.3
  • 13
    • 0037179698 scopus 로고    scopus 로고
    • Peginterferon alfa-2a plus ribavirin for chronic hepatitis c infection
    • Fried M.W., Shiffman M.L., Reddy K.R., et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis c infection. New England Journal of Medicine 2002, 347:975-982.
    • (2002) New England Journal of Medicine , vol.347 , pp. 975-982
    • Fried, M.W.1    Shiffman, M.L.2    Reddy, K.R.3
  • 14
    • 1542378867 scopus 로고    scopus 로고
    • Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirn dose
    • Hadziyannis S.J., Sette J.R., Morgan T.R., et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirn dose. Annals of Internal Medicine 2004, 140:346-355.
    • (2004) Annals of Internal Medicine , vol.140 , pp. 346-355
    • Hadziyannis, S.J.1    Sette, J.R.2    Morgan, T.R.3
  • 15
    • 0035934568 scopus 로고    scopus 로고
    • Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial
    • Manns M.P., McHutchinson J.G., Gordon S.C., et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet 2001, 358:958-965.
    • (2001) Lancet , vol.358 , pp. 958-965
    • Manns, M.P.1    McHutchinson, J.G.2    Gordon, S.C.3
  • 16
    • 84867767288 scopus 로고    scopus 로고
    • Safety profile of standard- vs. high-dose peginterferon alfa-2a plus standard-dose ribavirin in HCV genotype 1/4 patients: pooled analysis from 5 randomized studies
    • Marcellin P., Roberts S.K., Reddy K.R., et al. Safety profile of standard- vs. high-dose peginterferon alfa-2a plus standard-dose ribavirin in HCV genotype 1/4 patients: pooled analysis from 5 randomized studies. Expert Opinion on Drug Safety 2012, 11:901-909.
    • (2012) Expert Opinion on Drug Safety , vol.11 , pp. 901-909
    • Marcellin, P.1    Roberts, S.K.2    Reddy, K.R.3
  • 17
    • 84870427882 scopus 로고    scopus 로고
    • Response guided therapy in patients with chronic hepatitis C - yesterday, today and tomorrow
    • Ferenci P. Response guided therapy in patients with chronic hepatitis C - yesterday, today and tomorrow. Best Practice & Research Clinical Gastroenterology 2012, 26:463-469.
    • (2012) Best Practice & Research Clinical Gastroenterology , vol.26 , pp. 463-469
    • Ferenci, P.1
  • 18
    • 79960453276 scopus 로고    scopus 로고
    • EASL clinical practice guidelines: management of hepatitis C virus infection
    • Craxì A. EASL clinical practice guidelines: management of hepatitis C virus infection. Journal of Hepatology 2011, 55:245-264.
    • (2011) Journal of Hepatology , vol.55 , pp. 245-264
    • Craxì, A.1
  • 19
    • 77958029477 scopus 로고    scopus 로고
    • Practice guidelines for the treatment of hepatitis C: recommendations from an AISF/SIMIT/SIMAST
    • Practice guidelines for the treatment of hepatitis C: recommendations from an AISF/SIMIT/SIMAST. Expert Opinion Meeting Digestive and Liver Disease 2010, 42:81-91.
    • (2010) Expert Opinion Meeting Digestive and Liver Disease , vol.42 , pp. 81-91
  • 20
    • 20544443172 scopus 로고    scopus 로고
    • Peginterferon alpha-2b and RBV for 12 vs. 24 weeks in HCV genotype 2 and 3
    • Mangia A., Santoro R., Minerva N., et al. Peginterferon alpha-2b and RBV for 12 vs. 24 weeks in HCV genotype 2 and 3. New England Journal of Medicine 2005, 35:2609-2617.
    • (2005) New England Journal of Medicine , vol.35 , pp. 2609-2617
    • Mangia, A.1    Santoro, R.2    Minerva, N.3
  • 21
    • 38649090068 scopus 로고    scopus 로고
    • Pegylated interferon alfa and RBV for 14 versus 24 weeks in patients with hepatitis C virus genotype 2 or 3 and rapid virological response
    • Dalgard O., Bjoro K., Ring-Larsen H., et al. Pegylated interferon alfa and RBV for 14 versus 24 weeks in patients with hepatitis C virus genotype 2 or 3 and rapid virological response. Hepatology 2008, 47:35-42.
    • (2008) Hepatology , vol.47 , pp. 35-42
    • Dalgard, O.1    Bjoro, K.2    Ring-Larsen, H.3
  • 22
    • 23244457832 scopus 로고    scopus 로고
    • PegInterferon alpha 2a (Pegasys) plus RBV (Copegus) for 16 or 24 weeks in patients with HCV genotpe 2 and 3 chronic hepatitis C
    • von Wagner H., Huber H., Berg T., et al. PegInterferon alpha 2a (Pegasys) plus RBV (Copegus) for 16 or 24 weeks in patients with HCV genotpe 2 and 3 chronic hepatitis C. Gastroenterology 2005, 129:522-527.
    • (2005) Gastroenterology , vol.129 , pp. 522-527
    • von Wagner, H.1    Huber, H.2    Berg, T.3
  • 23
    • 0041822106 scopus 로고    scopus 로고
    • Early virologic response to treatment with peginterferon alpha 2b plus Ribavirin in patients with chronic hepatitis C
    • Davis G.L. Early virologic response to treatment with peginterferon alpha 2b plus Ribavirin in patients with chronic hepatitis C. Hepatology 2003, 38:645-652.
    • (2003) Hepatology , vol.38 , pp. 645-652
    • Davis, G.L.1
  • 24
    • 79958816097 scopus 로고    scopus 로고
    • Rapid virological response is the most important predictor of sustained virological response across genotypes in patients with chronic hepatitis C virus infection
    • Fried M.W., Hadziyannis S.J., Shiffman M.L., et al. Rapid virological response is the most important predictor of sustained virological response across genotypes in patients with chronic hepatitis C virus infection. Journal of Hepatology 2011, 55:69-75.
    • (2011) Journal of Hepatology , vol.55 , pp. 69-75
    • Fried, M.W.1    Hadziyannis, S.J.2    Shiffman, M.L.3
  • 25
    • 84870533049 scopus 로고    scopus 로고
    • High sustained virologic response rates in rapid virologic response patients in the large real-world PROPHESYS cohort confirm results from randomized clinical trials
    • Marcellin P., et al. High sustained virologic response rates in rapid virologic response patients in the large real-world PROPHESYS cohort confirm results from randomized clinical trials. Hepatology 2012, 56:2039-2050.
    • (2012) Hepatology , vol.56 , pp. 2039-2050
    • Marcellin, P.1
  • 26
    • 23444460553 scopus 로고    scopus 로고
    • Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin
    • Ferenci P., Fried M.W., Schiffman M.L., et al. Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin. Journal of Hepatology 2005, 43:425-433.
    • (2005) Journal of Hepatology , vol.43 , pp. 425-433
    • Ferenci, P.1    Fried, M.W.2    Schiffman, M.L.3
  • 27
    • 33748494889 scopus 로고    scopus 로고
    • Short-term treatment duration for HCV-2 and HCV-3 infected patients
    • Andriulli A., Dalgard O., Bjøro K., et al. Short-term treatment duration for HCV-2 and HCV-3 infected patients. Digestive and Liver Disease 2006, 38:741-748.
    • (2006) Digestive and Liver Disease , vol.38 , pp. 741-748
    • Andriulli, A.1    Dalgard, O.2    Bjøro, K.3
  • 28
    • 61949212724 scopus 로고    scopus 로고
    • Determinants of relapse after a short (12 weeks) course of antiviral therapy and re-treatment efficacy of a prolonged course in patients with chronic hepatitis C virus genotype 2 or 3 infection
    • Mangia A., Minerva N., Bacca D., et al. Determinants of relapse after a short (12 weeks) course of antiviral therapy and re-treatment efficacy of a prolonged course in patients with chronic hepatitis C virus genotype 2 or 3 infection. Hepatology 2009, 49:358-363.
    • (2009) Hepatology , vol.49 , pp. 358-363
    • Mangia, A.1    Minerva, N.2    Bacca, D.3
  • 29
    • 38649090347 scopus 로고    scopus 로고
    • Individualized treatment duration for hepatitis C Genotype 1 patients: a randomized controlled trial
    • Mangia A., Minerva N., Bacca D., et al. Individualized treatment duration for hepatitis C Genotype 1 patients: a randomized controlled trial. Hepatology 2008, 47:43-50.
    • (2008) Hepatology , vol.47 , pp. 43-50
    • Mangia, A.1    Minerva, N.2    Bacca, D.3
  • 30
    • 68949183162 scopus 로고    scopus 로고
    • Individualized treatment strategy according to early viral kinetics in hepatitis C virus type 1-infected patients
    • Berg T., Weich V., Teuber G., et al. Individualized treatment strategy according to early viral kinetics in hepatitis C virus type 1-infected patients. Hepatology 2009, 50:369-377.
    • (2009) Hepatology , vol.50 , pp. 369-377
    • Berg, T.1    Weich, V.2    Teuber, G.3
  • 31
    • 80054846451 scopus 로고    scopus 로고
    • Improved response to pegylated-interferon alfa-2b and ribavirin by individualizing treatment for 24-72 weeks
    • Sarrazin C., Schwendy S., Moller B., et al. Improved response to pegylated-interferon alfa-2b and ribavirin by individualizing treatment for 24-72 weeks. Gastroenterology 2011, 141:1656-1664.
    • (2011) Gastroenterology , vol.141 , pp. 1656-1664
    • Sarrazin, C.1    Schwendy, S.2    Moller, B.3
  • 32
    • 78851469540 scopus 로고    scopus 로고
    • Pre-treatment prediction of response to pegylated-interferon plus ribavirin for chronic hepatitis C using genetic polymorphism in IL28B and viral factors
    • Kurosaki M., Tanaka Y., Nishida N., et al. Pre-treatment prediction of response to pegylated-interferon plus ribavirin for chronic hepatitis C using genetic polymorphism in IL28B and viral factors. Journal of Hepatology 2011, 54:439-448.
    • (2011) Journal of Hepatology , vol.54 , pp. 439-448
    • Kurosaki, M.1    Tanaka, Y.2    Nishida, N.3
  • 33
    • 78650973933 scopus 로고    scopus 로고
    • IL28B genomic-based treatment paradigms for patients with chronic hepatitis c infection: the future of personalized HCV therapies
    • Clark P.J., Thompson A.J., McHutchison J. IL28B genomic-based treatment paradigms for patients with chronic hepatitis c infection: the future of personalized HCV therapies. American Journal of Gastroenterology 2011, 106:38-45.
    • (2011) American Journal of Gastroenterology , vol.106 , pp. 38-45
    • Clark, P.J.1    Thompson, A.J.2    McHutchison, J.3
  • 34
    • 84925580987 scopus 로고    scopus 로고
    • An IL28B polymorphism determines treatment response of hepatitis C virus genotype 2 or 3 patients who do not achieve a rapid virologic response
    • Mangia A., Thompson A.J., Santoro R., et al. An IL28B polymorphism determines treatment response of hepatitis C virus genotype 2 or 3 patients who do not achieve a rapid virologic response. Gastroenterology 2010, 139:821-827.
    • (2010) Gastroenterology , vol.139 , pp. 821-827
    • Mangia, A.1    Thompson, A.J.2    Santoro, R.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.